Roger L Kaspar from 525 Cress Rd, Santa Cruz, CA 95060, age 64, Phone: 8314200722

Resumes

Founder And Chief Executive Officer

view source

Location:

San Francisco, CA

Industry:

Biotechnology

Work:

Ayni Therapeutics
Founder and Chief Executive Officer
Somagenics, Inc. 2001 - 2004
Vice President of Biology
Transderm 2001 - 2004
Chief Executive Officer
Brigham Young University 1995 - 2001
Assistant Professor, Department of Chem and Biochem
Massachusetts Institute of Technology (Mit) 1991 - 1995
Post-Doctoral Associate

Education:

Brigham Young University 1986
Master of Science, Masters, Bachelors, Bachelor of Arts, Biochemistry, Chemistry University of Washington - School of Medicine
Doctorates, Doctor of Philosophy, Biochemistry

Skills:

Clinical Research
Molecular Biology
Biotechnology
Clinical Trials
Cell Biology
Biochemistry
Life Sciences
Rnai
Cell Culture
Lifesciences
Chemistry
Drug Discovery
Treatment
Pcr
Start Ups
Drug Development
Science
Genomics

Plumber

view source

Location:

Aurora, IL

Industry:

Consumer Goods

Work:

Thisone
Plumber

Us Patents

Inhibition Of Viral Gene Expression Using Small Interfering Rna
view source
US Patent:

7902351, Mar 8, 2011
Filed:

Jun 1, 2006
Appl. No.:

11/444901
Inventors:

Roger L. Kaspar - Santa Cruz CA, US
Heini Ilves - Santa Cruz CA, US
Attila A. Seyhan - Lafayette CO, US
Alexander V. Vlassov - Santa Cruz CA, US
Brian H. Johnston - Scotts Valley CA, US
Assignee:

SomaGenics Inc. - Santa Cruz CA
International Classification:

C07H 21/04
US Classification:

536 245
Abstract:

The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.

Inhibition Of Viral Gene Expression Using Small Interfering Rna
view source
US Patent:

8426380, Apr 23, 2013
Filed:

Mar 2, 2011
Appl. No.:

13/039100
Inventors:

Roger L. Kaspar - Santa Cruz CA, US
Heini Ilves - Santa Cruz CA, US
Attila A. Seyhan - San Jose CA, US
Alexander V. Vlassov - Santa Cruz CA, US
Brian H. Johnston - Scotts Valley CA, US
Assignee:

Somagenics, Inc. - Santa Cruz CA
International Classification:

C12N 15/11
C07H 21/04
US Classification:

514 44A, 536 245
Abstract:

The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.

Methods And Compositions For Treating Keratin Hyperproliferative Disorders
view source
US Patent:

8476243, Jul 2, 2013
Filed:

Dec 29, 2006
Appl. No.:

11/618138
Inventors:

Roger Louis Kaspar - Santa Cruz CA, US
Robyn Patricia Hickerson - Santa Cruz CA, US
Assignee:

Transderm, Inc. - Salt Lake City UT
International Classification:

C12N 15/11
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:

514 44A, 536 245
Abstract:

A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof.

Methods And Compositions For Transdermal Delivery Of Nucleotides
view source
US Patent:

8530436, Sep 10, 2013
Filed:

Jan 29, 2007
Appl. No.:

11/699772
Inventors:

Roger Kaspar - Santa Cruz CA, US
Assignee:

Transderm, Inc. - Salt Lake City UT
International Classification:

A61K 48/00
US Classification:

514 44, 536 245, 536 2431, 536 241
Abstract:

The present invention relates to formulations and related methods for transdermal delivery of nucleic acids. Specifically, the invention relates to a formulation containing lipids and an alcohol and which is capable of providing effective transdermal delivery of nucleic acid. The formulation can be used effectively to deliver nucleic acids for gene therapy and the treatment of disease.

Methods Of Preparation Of Gene-Specific Oligonucleotide Libraries And Uses Thereof
view source
US Patent:

20060051789, Mar 9, 2006
Filed:

Jul 1, 2005
Appl. No.:

11/173100
Inventors:

Sergei Kazakov - Los Gatos CA, US
Alexander Vlassov - Santa Cruz CA, US
Anne Dallas - Santa Cruz CA, US
Attila Seyhan - San Jose CA, US
Levente Egry - Santa Cruz CA, US
Heini Ilves - Santa Cruz CA, US
Roger Kaspar - Santa Cruz CA, US
Brian Johnston - Scotts Valley CA, US
International Classification:

C40B 40/08
C12P 19/34
US Classification:

435006000, 435091200
Abstract:

Methods of preparing gene-specific oligonucleotide libraries are disclosed. In one embodiment a double-stranded RNA corresponding to both sense and antisense strands of mRNA is digested by ribonuclease to produce short RNA fragments. In subsequent ligation steps, flanking oligoribonucleotides of defined sequences may be attached to the 3- and 5-ends of each fragment by RNA ligase (such as T4 RNA ligase). The products of ligation can be reverse transcribed and PCR amplified (RT-PCR) using the oligonucleotides attached to the gene-derived sequences as primer-binding sites. Various methods for incorporating libraries into expression vectors allowing expression of either siRNAs or shRNAs are also disclosed.

Methods Of Treating Keratin Hyperproliferation Disorders Using Mtor Inhibitors
view source
US Patent:

20080207672, Aug 28, 2008
Filed:

Nov 16, 2007
Appl. No.:

11/985850
Inventors:

Roger Louis Kaspar - Santa Cruz CA, US
Robyn Patricia Hickerson - Santa Cruz CA, US
International Classification:

A61K 31/436
A61P 17/00
US Classification:

514291
Abstract:

A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.

Small Interfering Rnas That Efficiently Inhibit Viral Expression And Methods Of Use Thereof
view source
US Patent:

20090170794, Jul 2, 2009
Filed:

Sep 12, 2005
Appl. No.:

11/662506
Inventors:

Roger L. Kaspar - Santa Cruz CA, US
Heine Ilves - Santa Cruz CA, US
Attila A. Seyhan - Lafayette CO, US
Alexander V. Vlassov - Santa Cruz CA, US
Brian H. Johnston - Scotts Valley CA, US
Assignee:

SomaGenics Inc. - Santa Cruz CA
International Classification:

A61K 31/7105
C12N 7/01
C07H 21/02
US Classification:

514 44, 4352351, 536 245
Abstract:

The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) which are useful for inhibition of viralmediated gene expression. Small interfering RNAs as described herein may be used in methods of treatment of HCV infection. ShRNA and siRNA constructs that target the internal ribosome entry site (IRES) sequence of HCV are described.

Microneedle Arrays For Active Agent Delivery
view source
US Patent:

20120150023, Jun 14, 2012
Filed:

Jun 9, 2011
Appl. No.:

13/157198
Inventors:

Roger L. Kaspar - Santa Cruz CA, US
Tycho Speaker - Santa Cruz CA, US
International Classification:

A61B 6/00
A61K 39/00
A61M 5/00
US Classification:

600424, 604173, 604506, 4241841
Abstract:

The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.